首頁 > 市場調查報告書 > 製藥

臨床開發

市場調查報告書

商品編碼

1679286

2030 年小鼠模型市場預測：按模型類型、技術、適應症、應用、最終用戶和地區進行的全球分析

Mice Model Market Forecasts to 2030 - Global Analysis By Model Type, Technology, Indication, Application, End User and By Geography

出版日期: 2025年03月03日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，全球小鼠模型市場預計在 2024 年將達到 15 億美元，到 2030 年將達到 27 億美元，預測期內的複合年成長率為 10.1%。小鼠模型由於小鼠與人類基因相似而成為研究人類疾病、生物過程和藥物開發的實驗工具。這些模型可幫助研究人員研究癌症、神經退化性疾病和心血管疾病等病症。有各種各樣的近交、雜交、基因改造、敲除和人源化模型可供選擇，每種模型都可以滿足特定的研究需求。 CRISPR-Cas9 和其他基因編輯技術正在提高這些模型針對疾病研究的精確度。

藥物研發對可靠的臨床前模型的需求日益增加

製藥和生物技術公司廣泛使用小鼠模型在臨床試驗前評估藥物功效和毒性，從而降低人體研究的失敗率。小鼠的生殖週期短，且基因與人類相似，非常適合進行快速、可擴展的實驗。 FDA 和 EMA 等監管機構要求提供大量的臨床前證據，這進一步推動了生物醫學研究中對小鼠模型的需求。癌症和神經系統疾病等慢性疾病的增加推動了對用於治療研究的複雜小鼠模型的需求。

道德問題和嚴格的動物試驗規定

PETA 和 HSUS 等動物權利組織積極反對在研究中使用動物模型，並提倡使用替代技術。研究機構必須支付更多費用來遵守有關動物試驗的嚴格規定，例如美國《動物福利法》和歐盟的《REACH》。此外，公眾壓力和企業減少動物試驗的承諾導致更多資金被投入到替代模型上，如類器官、In Silico模擬和人體晶片技術，從而阻礙了市場成長。

尖端基因改造技術開發

CRISPR-Cas9等現代基因改造方法大大提高了用於疾病研究的小鼠模型的準確性。科學家能夠精確地創建敲除、敲入和人源化小鼠模型，以便更好地為阿茲海默症、癌症和自體免疫疾病等疾病建立疾病模型。製藥公司、生物技術公司和研究機構之間的合作也推動了用於藥物測試和治療方法突破的客製化小鼠模型的創新。

基因工程模型高成本

培育、飼養和專門照顧基因改造和基因敲除小鼠的需求增加了研究成本。這種成本負擔通常會限制學術機構和小型實驗室獲得先進的小鼠模型。此外，基因改造模型的長期開發時間可能會推遲重要的研究項目，從而增加更便宜的替代品的吸引力。隨著 3D 細胞培養和人工智慧主導的藥物開發等替代研究技術的日益普及，小鼠模型的不斷成長的市場也受到了威脅。

COVID-19 的影響

COVID-19 疫情最初擾亂了實驗動物供應鏈，影響了研究時間表和臨床前測試活動。封鎖和旅行限制推遲了育種計劃並限制了研究設施的使用，阻礙了一系列生物醫學研究。但這場疫情也凸顯了小鼠模型在疫苗和抗病毒藥物開發中的重要性。人們對感染疾病模型的日益關注正推動對小鼠模型市場的重新投資，為其長期成長做好準備。

預測期內，近交系小鼠市場預計將佔最大佔有率

預計在預測期內，近交系小鼠將佔據最大的市場佔有率，因為基因的一致性保證了生物醫學研究的可重複性和一致性。該類小鼠廣泛應用於癌症研究、免疫學研究、毒理學測試等，並受到製藥和學術機構的青睞。此外，個人化醫療對可靠的臨床前模型的需求不斷成長，進一步推動了近交系小鼠的採用。

預測期內，腫瘤學領域預計將以最高複合年成長率成長

由於全球癌症負擔不斷增加以及對癌症研究先進臨床前模型的需求不斷成長，預計腫瘤學領域將在預測期內呈現最高的成長率。小鼠模型在研究腫瘤生物學、測試新型癌症治療方法以及臨床試驗前評估免疫療法的療效方面發揮重要作用。隨著研究人員尋求模擬人類腫瘤微環境的精確模型，對基因工程小鼠 (GEM)、患者來源異種移植 (PDX) 模型和人性化小鼠的需求正在激增。

佔比最大的地區：

在預測期內，預計北美將佔據最大的市場佔有率，這得益於其完善的研究基礎設施、對生物醫學研究的高投入以及製藥公司的強大影響力。美國在臨床前研究方面處於領先地位，大量資金來自美國國立衛生研究院 (NIH) 和私人生物技術公司等組織。該地區對藥物研發的興趣日益濃厚，再加上先進的基因工程能力，繼續推動對小鼠模型的需求。

複合年成長率最高的地區：

預計預測期內亞太地區將呈現最高的複合年成長率。這是由於中國、日本和印度等國家的政府對生物醫學研究的支持不斷增加、醫療成本不斷上升以及製藥業的擴張。此外，基因編輯技術的進步使得基因轉殖小鼠的使用率不斷提高。亞洲研究機構與全球製藥公司之間的合作研究正在進一步推動該地區的市場擴張。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

公司簡介
- 全面分析其他市場參與者（最多 3 家公司）
- 主要企業的 SWOT 分析（最多 3 家公司）
地理細分
- 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
競爭性基準化分析
- 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他歐洲國家
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 其他亞太地區
南美洲
- 阿根廷
- 巴西
- 智利
- 南美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 其他中東和非洲地區

第11章重大進展

協議、夥伴關係、合作和合資企業
收購與合併
新產品發布
業務擴展
其他關鍵策略

第12章公司概況

Allentown, LLC
Charles River Laboratories International, Inc.
Cyagen Biosciences Inc
Envigo
genOway SA
Harbour Biomed
Hera Biolabs
Inotiv
Janvier Labs
Ozgene Pty Ltd
PolyGene
Sage Labs
Taconic Biosciences, Inc.
The Jackson Laboratory
Trans Genic Inc.
TransCure bioServices

簡介目錄圖表

Product Code: SMRC28869

According to Stratistics MRC, the Global Mice Model Market is accounted for $1.5 billion in 2024 and is expected to reach $2.7 billion by 2030 growing at a CAGR of 10.1% during the forecast period. A mice model is a laboratory tool used to study human diseases, biological processes, and drug development due to mice's genetic similarity to humans. These models help researchers investigate conditions like cancer, neurodegenerative disorders, and cardiovascular diseases. Different types include inbred, outbred, transgenic, knockout, and humanized models, each serving specific research needs. CRISPR-Cas9 and other gene-editing technologies have enhanced the precision of these models for targeted disease studies.

Market Dynamics:

Driver:

Growing need for reliable preclinical models in drug discovery and development

The probability of failure in human research is decreased by the widespread use of mouse models by pharmaceutical and biotechnology companies to assess medication effectiveness and toxicity prior to clinical trials. Mice are perfect for quick and scalable experiments because of their short reproductive cycle and genetic resemblance to humans. The need for mouse models in biomedical research is further increased by regulatory bodies like the FDA and EMA, which want substantial preclinical evidence. The need for sophisticated mouse models for therapeutic research has increased due to the growth in chronic illnesses, such as cancer and neurological disorders.

Restraint:

Ethical concerns and stringent animal testing regulations

Animal rights groups like PETA and HSUS aggressively oppose the use of animal models in research and promote the use of alternative techniques. Research institutes must pay more to comply with strict regulations on animal testing, such as the Animal Welfare Act in the United States and the European Union's REACH. Additionally, there is now more money being spent on alternative models including organoids, in silico simulations, and human-on-a-chip technologies as a result of public pressure and business pledges to decrease animal experimentation hampers the market growth.

Opportunity:

Development of cutting-edge genetic modification techniques

Modern genetic alteration methods, such CRISPR-Cas9, have greatly increased the accuracy of mouse models used in illness research. Better disease modeling for diseases like Alzheimer's, cancer, and autoimmune illnesses is now possible because to scientists' ability to accurately generate knockout, knock-in, and humanized mouse models. Collaborations among pharmaceutical corporations, biotech businesses, and research institutes are also encouraging innovation in the creation of customized mouse models for drug testing and therapeutic breakthroughs.

Threat:

High costs associated with genetically engineered models

Higher research costs are a result of the breeding, housing, and specialized care needed for transgenic and knockout mice. The cost burden frequently prevents university institutions and small research labs from having access to sophisticated mouse models. Additionally, the lengthy development periods for genetically modified models may cause important research initiatives to be postponed, increasing the appeal of less expensive alternatives. The market expansion for mouse models is also threatened by the growing availability of alternative research techniques like 3D cell cultures and AI-driven drug development.

Covid-19 Impact

The COVID-19 pandemic initially disrupted the supply chain for laboratory animals, affecting research timelines and preclinical testing activities. Lockdowns and travel restrictions led to delays in breeding programs and limited access to research facilities, slowing down various biomedical studies. However, the pandemic also highlighted the importance of mice models in vaccine and antiviral drug development. This increased focus on infectious disease models has driven renewed investments in the mice model market, positioning it for long-term growth.

The inbred mice segment is expected to be the largest during the forecast period

The inbred mice segment is expected to account for the largest market share during the forecast period due to its genetic uniformity, which ensures reproducibility and consistency in biomedical research. These mice are extensively used in cancer research, immunology studies, and toxicology testing, making them a preferred choice for pharmaceutical and academic institutions. Additionally, the increasing demand for reliable preclinical models in personalized medicine is further driving the adoption of inbred mice.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate due to the rising global burden of cancer and the increasing need for advanced preclinical models for cancer research. Mice models play a crucial role in studying tumor biology, testing novel cancer therapies, and evaluating the efficacy of immunotherapies before clinical trials. The demand for genetically engineered mice (GEMs), patient-derived xenograft (PDX) models, and humanized mice has surged as researchers seek accurate models to mimic human tumor microenvironments.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its well-established research infrastructure, high investments in biomedical research, and strong presence of pharmaceutical companies. The U.S. leads in preclinical research, with extensive funding from organizations like the National Institutes of Health (NIH) and private biotech firms. The region's growing focus on drug discovery, coupled with advanced genetic engineering capabilities, continues to drive demand for mice models.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR attributed to increasing government support for biomedical research, rising healthcare expenditures, and expanding pharmaceutical industries in countries like China, Japan, and India. Additionally, the adoption of genetically modified mice models is increasing, driven by advancements in gene-editing technologies. Collaborations between Asian research institutes and global pharmaceutical companies are further fueling market expansion in this region.

Key players in the market

Some of the key players in Mice Model market include Allentown LLC, Charles River Laboratories International, Inc., Cyagen Biosciences Inc, Envigo, genOway S.A., Harbour Biomed, Hera Biolabs, Inotiv, Janvier Labs, Ozgene Pty Ltd, PolyGene, Sage Labs, Taconic Biosciences, Inc., The Jackson Laboratory, Trans Genic Inc. and TransCure bioServices .

Key Developments:

In February 2025, HBM Alpha Therapeutics Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone for various disorders.

In February 2025, Harbour BioMed and Insilico Medicine achieved strategic collaboration to advance AI-driven antibody discovery and development. leveraging their respective technological strengths in antibody discovery and artificial intelligence.

Model Types Covered:

Inbred Mice
Genetically Engineered Mice
Hybrid/ Congenic Mice
Outbred Mice
Conditioned/Surgically Modified Mice
Spontaneous Mutant Mice
Other Model Types

Technologies Covered:

CRISPR/Cas9
Microinjection
Embryonic Stem Cell Injection
Nuclear Transfer
Other Technologies

Indications Covered:

Oncology
Cardiovascular Diseases
Diabetes & Metabolic Disorders
Immunology & Inflammation
Central Nervous System Disorders
Genetic Diseases
Other Indications

Applications Covered:

Breeding Services
Cryopreservation
Quarantine
Rederivation
Genetic Testing
Model Licensing
Other Applications

End Users Covered:

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Contract Development & Manufacturing Organizations
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Mice Model Market, By Model Type

5.1 Introduction
5.2 Inbred Mice
5.3 Genetically Engineered Mice
5.4 Hybrid/ Congenic Mice
5.5 Outbred Mice
5.6 Conditioned/Surgically Modified Mice
5.7 Spontaneous Mutant Mice
5.8 Other Model Types

6 Global Mice Model Market, By Technology

6.1 Introduction
6.2 CRISPR/Cas9
6.3 Microinjection
6.4 Embryonic Stem Cell Injection
6.5 Nuclear Transfer
6.6 Other Technologies

7 Global Mice Model Market, By Indication

7.1 Introduction
7.2 Oncology
7.3 Cardiovascular Diseases
7.4 Diabetes & Metabolic Disorders
7.5 Immunology & Inflammation
7.6 Central Nervous System Disorders
7.7 Genetic Diseases
7.8 Other Indications

8 Global Mice Model Market, By Application

8.1 Introduction
8.2 Breeding Services
8.3 Cryopreservation
8.4 Quarantine
8.5 Rederivation
8.6 Genetic Testing
8.7 Model Licensing
8.8 Other Applications

9 Global Mice Model Market, By End User

9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.3 Academic & Research Institutes
9.4 Contract Research Organizations
9.5 Contract Development & Manufacturing Organizations
9.6 Other End Users

10 Global Mice Model Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Allentown, LLC
12.2 Charles River Laboratories International, Inc.
12.3 Cyagen Biosciences Inc
12.4 Envigo
12.5 genOway S.A.
12.6 Harbour Biomed
12.7 Hera Biolabs
12.8 Inotiv
12.9 Janvier Labs
12.10 Ozgene Pty Ltd
12.11 PolyGene
12.12 Sage Labs
12.13 Taconic Biosciences, Inc.
12.14 The Jackson Laboratory
12.15 Trans Genic Inc.
12.16 TransCure bioServices

簡介目錄圖表

List of Tables

Table 1 Global Mice Model Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Mice Model Market Outlook, By Model Type (2022-2030) ($MN)
Table 3 Global Mice Model Market Outlook, By Inbred Mice (2022-2030) ($MN)
Table 4 Global Mice Model Market Outlook, By Genetically Engineered Mice (2022-2030) ($MN)
Table 5 Global Mice Model Market Outlook, By Hybrid/ Congenic Mice (2022-2030) ($MN)
Table 6 Global Mice Model Market Outlook, By Outbred Mice (2022-2030) ($MN)
Table 7 Global Mice Model Market Outlook, By Conditioned/Surgically Modified Mice (2022-2030) ($MN)
Table 8 Global Mice Model Market Outlook, By Spontaneous Mutant Mice (2022-2030) ($MN)
Table 9 Global Mice Model Market Outlook, By Other Model Types (2022-2030) ($MN)
Table 10 Global Mice Model Market Outlook, By Technology (2022-2030) ($MN)
Table 11 Global Mice Model Market Outlook, By CRISPR/Cas9 (2022-2030) ($MN)
Table 12 Global Mice Model Market Outlook, By Microinjection (2022-2030) ($MN)
Table 13 Global Mice Model Market Outlook, By Embryonic Stem Cell Injection (2022-2030) ($MN)
Table 14 Global Mice Model Market Outlook, By Nuclear Transfer (2022-2030) ($MN)
Table 15 Global Mice Model Market Outlook, By Other Technologies (2022-2030) ($MN)
Table 16 Global Mice Model Market Outlook, By Indication (2022-2030) ($MN)
Table 17 Global Mice Model Market Outlook, By Oncology (2022-2030) ($MN)
Table 18 Global Mice Model Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
Table 19 Global Mice Model Market Outlook, By Diabetes & Metabolic Disorders (2022-2030) ($MN)
Table 20 Global Mice Model Market Outlook, By Immunology & Inflammation (2022-2030) ($MN)
Table 21 Global Mice Model Market Outlook, By Central Nervous System Disorders (2022-2030) ($MN)
Table 22 Global Mice Model Market Outlook, By Genetic Diseases (2022-2030) ($MN)
Table 23 Global Mice Model Market Outlook, By Other Indications (2022-2030) ($MN)
Table 24 Global Mice Model Market Outlook, By Application (2022-2030) ($MN)
Table 25 Global Mice Model Market Outlook, By Breeding Services (2022-2030) ($MN)
Table 26 Global Mice Model Market Outlook, By Cryopreservation (2022-2030) ($MN)
Table 27 Global Mice Model Market Outlook, By Quarantine (2022-2030) ($MN)
Table 28 Global Mice Model Market Outlook, By Rederivation (2022-2030) ($MN)
Table 29 Global Mice Model Market Outlook, By Genetic Testing (2022-2030) ($MN)
Table 30 Global Mice Model Market Outlook, By Model Licensing (2022-2030) ($MN)
Table 31 Global Mice Model Market Outlook, By Other Applications (2022-2030) ($MN)
Table 32 Global Mice Model Market Outlook, By End User (2022-2030) ($MN)
Table 33 Global Mice Model Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
Table 34 Global Mice Model Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
Table 35 Global Mice Model Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
Table 36 Global Mice Model Market Outlook, By Contract Development & Manufacturing Organizations (2022-2030) ($MN)
Table 37 Global Mice Model Market Outlook, By Other End Users (2022-2030) ($MN)